Efficacy of second-line targeted agents in kras wild metastatic colorectal cancer patients who received prior targeted agent: First anti-epidermal growth factor receptor or vascular endothelial growth factor in right and left colon?. (June 2020)

• Record Type: Journal Article
• Authors: Dogan, Ender; Firat, Sedat T; Cosar, Ramazan; Bozkurt, Oktay; Inanc, Mevlude; Ozkan, Metin
• Is Part Of: Journal of oncology pharmacy practice. Volume 26:Number 4(2020)
• Page Start: 781
• Page End: 786
• Publication Date: 2020-06
• Subjects: Metastatic colon cancer -- anti-EGFR -- anti-VEGF; Cancer -- Chemotherapy -- Periodicals; Clinical pharmacology -- Periodicals; 616.994061
• DOI: 10.1177/1078155219856682
• Languages: English
• ISSNs: 1078-1552

Abstract

Introduction: We aimed to investigate the impact of first biological agents on second-line biological agents in kras wild-type metastatic colon patients in right and left colon. Patients and methods: The patients received anti-EGFR compared with anti-VEGF in right and left colon separately according to progression-free survival and overall survival in second line. Results: A total of 84 patients were included in the study. In left colon, progression-free survival and overall survival were 9 and 14 months for anti-EGFR and 9 and 16 months for anti-VEGF in the second line. In right colon, progression-free survival and overall survival were 5 and 9 months for anti-EGFR and 4 and 6 months for anti-VEGF in the second line. Conclusions: Progression-free survival was higher in patients who received bevacizumab first followed by anti-EGFR than reverse sequencing in right colon. Overall survival was similar between two groups.